Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 12:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 20,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Recruiting Not applicable Interventional

Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation

NCT07396987
View directory record Official record
Conditions
Asthma Attack, Asthma Control, Asthma Exacerbations, Asthma
Interventions
ER-Initiated Telehealth Referral
Behavioral
Lead sponsor
Juan Carlos Cardet
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 12:02 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

NCT04855136
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BB2121, CC-220, BMS-986405
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Phase 1 Interventional

Haplo Peripheral Blood Sct In GVHD Prevention

NCT04473911
View directory record Official record
Conditions
GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma
Interventions
FLUDARABINE, CYCLOPHOSPHAMIDE, TBI, Melphalan, Sirolimus, Mycophenolate mofetil, RGI-2001
Drug · Radiation
Lead sponsor
Zachariah Michael DeFilipp
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions

NCT01659892
View directory record Official record
Conditions
Asthma
Interventions
Montelukast, Singulair
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 29, 2026, 12:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Adults for Asthma Microbiome Research Studies

NCT02887911
View directory record Official record
Conditions
Asthma, Healthy
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 29, 2026, 12:02 AM EDT
Not yet recruiting Not applicable Interventional

Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis

NCT07181811
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments
Other
Lead sponsor
Anza Memon
Federal
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Phase 1 Interventional

A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

NCT00002111
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 12:02 AM EDT
Completed No phase listed Observational

Evaluation of ST2 and IL-33 in Patients Presenting to the Emergency Department With Trouble Breathing

NCT00707811
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma, Pulmonary Embolism, Pneumonia, Congestive Heart Failure
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Not applicable Interventional

Omega-3 Replacement With Krill Oil in Disease Management of SLE

NCT03626311
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
AKBM-3031, Placebo
Dietary Supplement · Other
Lead sponsor
Aker BioMarine Human Ingredients AS
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 29, 2026, 12:02 AM EDT
Terminated Not applicable Interventional Results available

Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

NCT03906227
View directory record Official record
Conditions
ANCA Associated Vasculitis
Interventions
ENUMERATION OF CD5+ B Cells
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 29, 2026, 12:02 AM EDT
Terminated No phase listed Observational

How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes

NCT03370861
View directory record Official record
Conditions
Autoimmunity, Melanoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma of the Skin, Basal Cell Carcinoma, Skin Cancer
Interventions
Immunotherapy
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

NCT02921061
View directory record Official record
Conditions
Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Decitabine, Filgrastim, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Asthma and Mindfulness-Based Stress Reduction (MBSR)

NCT00682669
View directory record Official record
Conditions
Asthma
Interventions
MBSR, HLC
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Results available

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

NCT01728805
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
KW-0761, Vorinostat
Biological · Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
34
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Phase 1 Interventional

The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months

NCT00006279
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants

NCT00000873
View directory record Official record
Conditions
HIV Infections
Interventions
Infant Formula
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 17 Days
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 29, 2026, 12:02 AM EDT
Terminated Phase 2 Interventional Results available

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

NCT01548573
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Tandem autologous stem cell transplant, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide, Bortezomib, Thalidomide, Melphalan
Drug · Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Not applicable Interventional Results available

Robotic Arm Assisted Total Knee Arthroplasty

NCT02058069
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis
Interventions
Robotic Arm Assisted Total Knee Arthroplasty
Device
Lead sponsor
MAKO Surgical Corp.
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
St. Helena, California • Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Results available

Intravenous Immunoglobulin for PANDAS

NCT01281969
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Children, Anxiety Disorder, Autoimmune Disease, PANDAS
Interventions
Gamunex Intravenous Immunoglobulin, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
4 Years to 13 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Phase 3 Interventional

Directly Observed Therapy in High Risk Populations in Newark, NJ

NCT00285883
View directory record Official record
Conditions
Directly Observed Therapy, HIV Infections
Interventions
Invirase, Norvir
Drug
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2006 · Synced Oct 29, 2026, 12:02 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Estrogen and Gender Biased Autoimmunity

NCT00519454
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Peripheral lab draws
Other
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 29, 2026, 12:02 AM EDT
Terminated Phase 4 Interventional Results available

Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)

NCT00796705
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Adalimumab placebo, Etanercept
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 29, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Results available

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

NCT05202262
View directory record Official record
Conditions
Asthma
Interventions
BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BD MDI 320 μg, Open-label Symbicort TBH 320/9 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
66
States / cities
Chandler, Arizona • Tucson, Arizona • Bakersfield, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 29, 2026, 12:02 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

NCT01585688
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions
hLL1-DOX (IMMU-115)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Newark, Delaware • Orlando, Florida • Goshen, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 29, 2026, 12:02 AM EDT